Trials / Completed
CompletedNCT03952806
Study of BHV-3241 in Participants With Multiple System Atrophy
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 421 (actual)
- Sponsor
- Biohaven Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Verdiperstat | 300mg 2 oral tablets, twice daily |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2019-07-29
- Primary completion
- 2021-07-29
- Completion
- 2022-06-30
- First posted
- 2019-05-16
- Last updated
- 2023-09-29
- Results posted
- 2023-09-29
Locations
48 sites across 6 countries: United States, Austria, France, Germany, Italy, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03952806. Inclusion in this directory is not an endorsement.